The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Gene Therapy With Adeno-Associated Virus Vector 5-Human Factor IX in Adults With Hemophilia B
Open accessAbstract
Key Points: AAV5 liver-directed wild-type hFIX gene transfer was well tolerated and clinically effective in severe and moderate-severe hemophilia B. No cellular immune responses to the AAV5 vector were detected, and FIX expression levels were stable for the entire observation period.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While we have not tested CpG depletion in scAAV vectors in this study, clinical trial results support that such a vector is also less prone to CD8+ T cell activation, at least against capsid (47, 52).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Approximately 5 subjects across 3 trials experienced self-limited, vector-infusion reactions at doses of 2 × 1012−6 × 1013 vg/kg, characterized by fever, myalgias, and/or hypotension, which appear consistent with an innate immune response.141,150,152”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [141]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 1×
“This is longer than reported in the trial of scAAV2/8-LP1-hFIXco, in which clearance was reported by day 60.(12) Likewise,”
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067659 · Cited by 1,950 · cited 1×
“Hemophilia Joint Health Scores‡ 27 (2-49) 6 (0-17)”
Guidelines for the management of hemophilia
Srivastava, A., Brewer, A. K., Mauser‐Bunschoten, E. P., Key, N. S., Kitchen, S., Llinas, A., Ludlam, C. A., Mahlangu, J. N., Mulder, K., Poon, M. C., et al. (2013) · Haemophilia · doi:10.1111/j.1365-2516.2012.02909.x · Cited by 1,927
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864 · cited 1×
“Hemophilia Joint Health Scores‡ 27 (2-49) 6 (0-17)”
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273 · cited 1×
“Hemophilia Joint Health Scores‡ 27 (2-49) 6 (0-17)”
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970 · cited 1×
“Hemophilia Joint Health Scores‡ 27 (2-49) 6 (0-17)”
White, G. C., Rosendaal, F. R., Aledort, L. M., Lusher, J. M., Rothschild, C., & Ingerslev, J. (2001) · PubMed · Cited by 798
Rosendaal, F., Aledort, L., Lusher, J., Rothschild, C., Ingerslev, J., & White, G. (2001) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1615621 · Cited by 786 · cited 1×
“Gene transfer is particularly attractive for the treatment of hemophilia since even a modest rise in clotting factor activity can substantially attenuate the bleeding risk.(9) Durable FIX expression was recently demonstrated in ten participants who received a single infusion of adeno-associated virus (AAV) serotype ei…”
X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua)
Simioni, P., Tormene, D., Tognin, G., Gavasso, S., Bulato, C., Iacobelli, N. P., Finn, J. D., Spiezia, L., Radu, C., & Arruda, V. R. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904377 · Cited by 394 · cited 1×
“Hemophilia Joint Health Scores‡ 27 (2-49) 6 (0-17)”
Halbert, C. L., Miller, A. D., Mcnamara, S., Emerson, J., Gibson, R. L., Ramsey, B., & Aitken, M. L. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.440 · Cited by 227
Research works printed but not linked: 3
- Pasi, 2017, Interim results from a phase 1/2 AAV5-FVIII gene transfer in patients with severe hemophilia A, Res Pract Thromb Haemost., 1, 1
- Chapin, 2017, An analysis of bleeding rates and factor IX consumption in the phase I/II BAX 335 gene therapy trial in subjects with hemophilia B, Res Pract Thromb Haemost., 1, 144
- Nathwani, 2016, Progress for gene therapy for hemophilia. European Society of Gene and Cell Therapy
Cited by
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Hinderer, C., Katz, N., Buza, E. L., Dyer, C., Goode, T., Bell, P., Richman, L. K., & Wilson, J. M. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.015 · Cited by 814
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
Mahlangu, J., Oldenburg, J., Paz-Priel, I., Negrier, C., Niggli, M., Mancuso, M. E., Schmitt, C., Jiménez-Yuste, V., Kempton, C., Dhalluin, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1803550 · Cited by 763
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
“Approximately 5 subjects across 3 trials experienced self-limited, vector-infusion reactions at doses of 2 10(12) 6 10(13) vg/kg, characterized by fever, myalgias, and/or hypotension, which appear consistent with an innate immune response.(141,150,152) Hints of dose-limiting toxicities of systemic AAV infusion are sup…”
BackgroundAAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
Metadata
- Authors
- Miesbach, W., Meijer, K., Coppens, M., Kampmann, P., Klamroth, R., Schutgens, R., Tangelder, M., Castaman, G., Schwäble, J., Bonig, H., Seifried, E., Cattaneo, F., Meyer, C., & Leebeek, F. W. G.
- Affiliations
- University Hospital Frankfurt (DE)
- University Medical Center Groningen (NL)
- Amsterdam UMC Location University of Amsterdam (NL)
- Rigshospitalet (DK)
- Vivantes Klinikum (DE)
- Utrecht University (NL)
- UniQure (Netherlands) (NL)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- German Red Cross (DE)
- University of Washington (US)
- Chiesi (Italy) (IT)
- Erasmus MC (NL)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2018-03-01
- Volume
- 131
- Issue
- 9
- Pages
- 1022-1031
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC5833265
- OpenAlex
- W2773565340
- Cited by
- 301
- References
- 29
- Citations by year
- 2026: 9 · 2025: 26 · 2024: 26 · 2023: 35 · 2022: 44 · 2021: 44 · 2020: 46 · 2019: 40 · 2018: 30
- FWCI
- 24.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- gene therapy, human factor IX, hemophilia B, factor IX activity, alanine aminotransferase elevation, adults
- MeSH terms
- Dependovirus, Adult, Hemophilia B, Factor IX, Female, Genetic Vectors, Humans, Male, Prednisolone, Genetic Therapy, Parvovirinae
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gene Therapy With Adeno-Associated Virus Vector 5-Human Factor IX in Adults With Hemophilia B. https://app.cochat.ai/papers/10.1182/blood-2017-09-804419
- The paper
- Miesbach, W., Meijer, K., Coppens, M., Kampmann, P., Klamroth, R., Schutgens, R., Tangelder, M., Castaman, G., Schwäble, J., Bonig, H., Seifried, E., Cattaneo, F., Meyer, C., & Leebeek, F. W. G. (2018). Gene Therapy With Adeno-Associated Virus Vector 5-Human Factor IX in Adults With Hemophilia B. Blood. https://doi.org/10.1182/blood-2017-09-804419
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.